Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2021 April;112(2) > Minerva Medica 2021 April;112(2):201-14

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  HEPATITIS C INFECTION: A SYSTEMIC DISEASE 

Minerva Medica 2021 April;112(2):201-14

DOI: 10.23736/S0026-4806.20.07158-X

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Rheumatologic manifestations of Hepatitis C Virus

Elena TREPPO 1, Luca QUARTUCCIO 1 , Gaafar RAGAB 2, Salvatore DE VITA 1

1 Department of Medicine, Rheumatology Clinic, University of Udine, ASUFC, Udine, Italy; 2 Unit of Rheumatology and Clinical Immunology, Department of Internal Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt



INTRODUCTION: Hepatitis C Virus (HCV) is a well-known worldwide infection, responsible for hepatic and extrahepatic complications. Among extrahepatic manifestation, the rheumatologic are the most common ones. With the arrival of Direct Antiviral Agents (DAA), the treatment and the clinical perspective have rapidly changed, permitting to achieve a sustained virological response (SVR) and preventing complications of chronic infection.
EVIDENCE ACQUISITION: We performed on PubMed a literature search for the articles published by using the search terms “HCV infection,” “HCV syndrome,” “HCV-related rheumatologic disorders,” “cryoglobulinemia,” “cryoglobulinemic vasculitis” and “mixed cryoglobulinemia.”
EVIDENCE SYNTHESIS: Mixed cryoglobulinemia (MC) is the prototype of HCV-associated rheumatologic disorder. HCV-related MC is typically considered by physicians as a human model disease to linking infection with autoimmune diseases. Chronic HCV infection can lead to a multistep process from a simple serological alteration (presence of circulating serum cryoglobulins) to frank systemic vasculitis (cryoglobulinemic vasculitis [CV]) and ultimately to overt malignant B lymphoproliferation (such as non-Hodgkin lymphoma [NHL]). Antiviral therapy is indicated to eradicate the HCV infection and to prevent the complications of chronic infection. Immunosuppressive therapy is reserved in case of organ threatening manifestations of CV. In this review, we discuss the main clinical presentation, diagnostic approach and treatment of rheumatologic manifestations of HCV infection.
CONCLUSIONS: Chronic HCV infection is responsible for complex clinical condition, ranging from hepatic to extra-hepatic disorders. Cryoglobulins are the result of this prolonged immune system stimulation, caused by tropism of HCV for B-lymphocyte.


KEY WORDS: Hepatitis C; Cryoglobulinemia; Vasculitis; Sjögren’s Syndrome; Antiviral agents

top of page